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Plasma angiopoietin-like 4 is related to
phospholipid transfer protein activity in
diabetic and non-diabetic subjects:
role of enhanced low grade inflammation
Eke G. Gruppen1, Sander Kersten2 and Robin P. F. Dullaart1*
Abstract
Background: Angiopoietin-like 4 (ANGPTL4) inhibits lipoprotein lipase, whereas phospholipid transfer protein (PLTP)
enhances hepatic triglyceride secretion. Both factors may be upregulated by inflammatory pathways. Since the
extent to which these circulating factors are interrelated is unknown, we determined the relationship between
plasma ANGPTL4 and PLTP activity, and assessed whether such a relationship could be explained by high sensitivity
C-reactive protein (hsCRP) levels as a marker of low-grade chronic inflammation.
Methods: Fasting plasma ANGPTL4, PLTP activity (liposome-vesicle high density lipoprotein system) and hsCRP
were measured in 41 type 2 diabetic (T2DM) subjects and 36 non-diabetic subjects.
Results: Plasma ANGPTL4 and PLTP activity were increased in T2DM (p < 0.001 for each), coinciding with elevated
hsCRP, triglycerides and non-esterified fatty acids (NEFA) (p = 0.031 to 0.001). In univariate analysis, ANGTLP4 was
correlated with PLTP activity (Rs = 0.309, p = 0.006), whereas both factors were related to hsCRP and NEFA levels
(Rs = 0.304 to 0.411, p < 0.01 to < 0.001). In multivariable linear regression analysis adjusting for age, sex, glucose,
total cholesterol, triglycerides and NEFA, ANGPTL4 and PLTP activity each remained positively associated with hsCRP
(β = 0.315, p = 0.003 and β = 0.299, p = 0.034, respectively). Plasma ANGPTL4 remained positively associated with
PLTP activity when taking account of age, sex, glucose, total cholesterol, triglycerides and NEFA (β = 0.315,
p = 0.003). Notably, this association disappeared after further adjustment for hsCRP (β = 0.131, p = 0.25).
Conclusions: In conclusion, plasma ANGPTL4 and PLTP activity are interrelated, which may at least in part be
explained by low-grade chronic inflammation. A pro-inflammatory state could affect triglyceride metabolism via
concerted effects on ANGPTL4 and PLTP.
Keywords: Angiopoietin-like4, High sensitivity C-reactive protein, Non-esterified fatty acids,
Phospholipid transfer protein activity, Type 2 diabetes mellitus
Background
During the past few years, the key role of angiopoietin
like proteins (ANGPTL) in lipid metabolism and energy
balance is increasingly appreciated [1–3]. Among this
family of proteins, ANGPTL4 is a secreted glycoprotein
that is highly expressed in liver and adipose tissue [1–3].
Evidence abounds that ANGPTL4 functions as an
inhibitor of lipoprotein lipase, thereby attenuating the
uptake of triglyceride-rich lipoprotein-derived fatty acids
in several cell types including adipocytes [2]. Import-
antly, non-esterified fatty acids (NEFA) serve as potent
activators of ANGPTL4 expression in several tissues,
which is mediated by peroxisome proliferator-activated
receptors (PPARs) [2, 4–7]. Consistent with these data,
circulating ANGPTL4 concentrations have been
reported to correlate positively with plasma NEFA,
although this relationship has not been consistently
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observed, while a relationship with fasting triglycerides
appears to be modest or even absent [8–10].
The metabolism of triglycerides is also governed by
phospholipid transfer protein (PLTP), a lipid transfer pro-
tein that is produced by a variety of cell systems, including
hepatocytes, adipocytes and macrophages [11–13]. PLTP
transfers phospholipids between lipoproteins, and con-
verts high density lipoproteins (HDL) to smaller and lar-
ger particles [11–13]. Of note, studies in transgenic mice
have shown that PLTP deficiency attenuates the secretion
of very low density lipoproteins (VLDL) by the liver,
whereas PLTP overexpression has the opposite effect
[14, 15]. Moreover, studies in humans have shown that
plasma PLTP activity is increased after a prolonged ex-
posure to an intravenously administered triglyceride
emulsion, while a decrease has been observed when
plasma NEFA availability is attenuated by Acipimox ad-
ministration [16, 17].
Interestingly, recent evidence has linked ANGPTL4
regulation to inflammatory pathways. Specifically, treat-
ment of mice with lipopolysaccharide or zymosan was
shown to increase ANGPTL4 expression in several tis-
sues [18]. Furthermore, Angptl4 mRNA and protein
levels are upregulated by various inflammatory stimuli in
human THP1 macrophages in vitro [10]. Clinically,
plasma ANGPTL4 correlates positively with high sensi-
tivity C-reactive protein (hsCRP), an established marker
of enhanced low-grade inflammation [8, 10, 19]. Accord-
ingly, the plasma ANGPTL4 concentration is likely to be
elevated in subjects with pro-inflammatory conditions
such as the metabolic syndrome and Type 2 diabetes
mellitus (T2DM) [9, 10, 20]. Notably, plasma PLTP
activity is associated with enhanced low-grade chronic
inflammation as well, as evidenced by its positive rela-
tionship with hsCRP [21–23]. In keeping with a role of
inflammation in the regulation of this lipid transfer
protein, plasma PLTP activity is elevated during the
acute phase of sepsis in humans [24]. Taken together,
these data [10, 21–23] support the hypothesis that en-
hanced low-grade inflammation, as reflected by plasma
hsCRP, may result in upregulation of both circulating
ANGPTL4 and PLTP activity. Pathophysiologically, such
a relationship between ANGPTL4 and PLTP would con-
ceivably link a pro-inflammatory state to alterations in
triglyceride metabolism. Since diabetic dyslipidemia is fea-
tured by abnormalities in triglyceride metabolism [10, 11],
it is relevant to study ANGPTL4 and PLTP activity
together in T2DM.
In the absence of any data concerning the possible re-
lationship between circulating ANGPTL4 levels and
PLTP activity, we initiated the present study to deter-
mine i) the extent to which plasma ANGPTL4 relates to
PLTP activity among subjects with and without T2DM,
and ii) whether such a relationship may be explained at
least in part by an association of low-grade chronic in-




The study protocol was approved by the medical ethics
committee of the University Medical Center Groningen,
and written informed consent had been obtained from
all participants. Subjects with and without T2DM were
aged > 18 years, and were recruited by advertisement in
local newspapers. T2DM had been diagnosed by primary
care physicians applying guidelines from the Dutch
College of General Practitioners (fasting plasma glucose
≥ 7.0 mmol/l; non-fasting plasma glucose ≥ 11.1 mmol/l).
The use of metformin, sulfonylurea was allowed but
insulin use was an exclusion criterion. Subjects taking
antihypertensive medication were also allowed to partici-
pate. Subjects with a history of cardiovascular disease,
chronic kidney disease (estimated glomerular filtration
rate < 60 ml/min/1.73 m2 and/or proteinuria), abnormal
liver function tests (transaminases > 3 times the upper
reference limit) or thyroid dysfunction (thyroid
stimulating hormone > 10 or < 0.40 mU/l or use of
thyroid function influencing medication), as well as
current smokers and subjects who used lipid lowering
drugs were also excluded.
Blood pressure was measured after 15 min rest at the
left arm in sitting position using a sphygmomanometer.
Body mass index (BMI in kg/m2) was calculated as
weight divided by height squared. The participants were
studied after an overnight fast.
Laboratory analyses
Serum and EDTA-anticoagulated plasma samples were
stored at − 80 °C until analysis. Plasma glucose was mea-
sured shortly after blood collection with an APEC glu-
cose analyzer (APEC Inc., Danvers, MA, USA). Plasma
NEFA were measured with a kit from Wako Diagnostics
(HR Series NEFA-HR(2), Wako Chemicals GmbH,
Neuss, Germany). Plasma total cholesterol and triglycer-
ides were measured by routine enzymatic methods
(Roche/Hitachi cat. Nos 11,875,540 and 1,187,602,
respectively; Roche Diagnostics GmBH, Mannheim,
Germany). HDL cholesterol was assayed by a homoge-
neous enzymatic colorimetric test (Roche/Hitachi, cat.no
04713214). Non-HDL cholesterol was calculated as the
difference between total cholesterol and HDL
cholesterol. Low density lipoprotein (LDL) cholesterol
was calculated by the Friedewald formula in case of tri-
glycerides < 4.5 mmol/l. Apolipoprotein A-I (apoA-I)
and apolipoprotein B (apoB) were measured by immu-
noturbidimetry (Roche/Cobas Integra Tinaquant cat no.
03032566, Roche Diagnostics). hsCRP was assayed by
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nephelometry with a lower limit of 0.175 mg/l (BNII N;
Dade Behring, Marburg, Germany). HbA1c was
measured by high-performance liquid chromatography
(Bio-Rad, Veenendaal, the Netherlands; normal range:
27–43 mmol/mol).
Plasma ANGPTL4 was assayed by enzyme-linked im-
munosorbent assay (ELISA) as described [5, 10]. In brief,
96-well plates were coated with anti-human ANGPLT4
polyclonal goat IgG antibody (AF3485, R&D systems
Netherlands, Abingdon, Oxon, UK) and incubated over-
night at 4 °C. After 4 washes with 300 μL phosphate
buffered saline (PBS)-Tween20 0.1%, 300 μl of blocking
solution (PBS containing 1% bovine serum albumin) was
added per well and left for 1 h at room temperature
under gentle agitation. 100 μl of 20-fold diluted human
plasma was applied to each well, followed by 2 h incuba-
tion at room temperature under gentle agitation. A
standard curve was prepared with recombinant human
ANGPTL4 (3485-AN, R&D systems). This procedure
was followed by adding 100 μL of diluted biotinylated
anti-human ANGPTL4 polyclonal goat IGG antibody
(BAF3485, R&D systems) for 2 h, followed by addition
of streptavidin-conjugated horseradish peroxidase for
20 min, and tetramethyl benzidine substrate reagent
for 6 min. The reaction was stopped by adding 50 μl
of 10% H2SO4, and the absorbance was measured at
450 nm. The intra-assay coefficient of variation (CV)
is 7%. Plasma PLTP activity was assayed with a
phospholipid vesicles-HDL system, using [14C]-labeled
dipalmitoyl phosphatidylcholine as described [25, 26].
The phospholipid transfer promoting properties of
cholesteryl ester transfer protein do not interfere with
this excess exogenous substrate assay. The method is
specific for PLTP activity, and represents the level of
active PLTP [25]. Plasma PLTP activity (expressed in
arbitrary units (AU); 100 AU corresponds to 13.
6 μmol phosphatidylcholine transferred per mL
plasma per hour) was related to its activity in
reference human pool plasma, and was measured in
duplicate. The inter-assay CV amounts to 5%.
Statistical analysis
IBM SPSS software (SPSS, version 22.0, SPSS Inc.
Chicago, IL, USA) was used for data analysis. Data are
expressed in medians (interquartile ranges). Between
group differences in variables were determined by
Mann-Whitney U tests and Chi-square tests where ap-
propriate. Univariate correlations were determined by
Spearman correlation coefficients. Multivariable linear
regression analyses were carried out to disclose the inde-
pendent relationships of ANGPTL4 and PLTP activity
separately with hsCRP taking account of glycemia, NEFA
and lipid levels. Additional analysis were done to discern
the influence of hsCRP on the relationship between
ANGPTL4 and PLTP activity. In these analyses,
ANGPTL4, triglycerides and hsCRP were loge trans-
formed to achieve approximately normal distributions.
Two-sided p-values < 0.05 were considered statistically
significant.
Results
We studied 41 subjects with T2DM and 36 non-diabetic
subjects (Table 1). Besides dietary advice which had been
given to all diabetic subjects, metformin was taken by 5
individuals, and sulfonylurea by 6 individuals; 14 partici-
pants used both drugs. The diabetic subjects did not
take other glucose lowering drugs. Additionally, anti-
hypertensive drugs, particularly angiotensin-converting
enzyme inhibitors, angiotensin II receptor antagonists
and diuretics, alone or in combination were used by 19
T2DM subjects. None of the non-diabetic subjects used
anti-hypertensive drugs. Three non-diabetic women
were using estrogens. Other medications were not taken.
The T2DM subjects were older than the non-diabetic
participants; the difference in sex distribution between
T2DM and non-diabetic subjects was not significant
(Table 1). Blood pressure, BMI, fasting glucose, HbA1c,
hsCRP and fasting NEFA levels were higher in T2DM
subjects (Table 1). Total cholesterol, non-HDL choles-
terol, LDL cholesterol and apoB levels were not different
between diabetic and non-diabetic subjects. Triglycerides
were elevated in T2DM subjects, coinciding with lower
HDL cholesterol and apoA-I. Plasma ANGPTL4 levels
and PLTP activity were each higher in T2DM subjects
than in non-diabetic subjects (Table 1). ANGPTL4 and
PLTP activity were not different in men vs. women
(ANGPTL4: 5.24 (4.13–6.01) μg/l in men and 4.35 (3.
03–6.10) μg/l in women, p = 0.17; PLTP activity: 97.9
(92.4–103.7) AU in men and 100.2 (91.6–110.5) AU in
women, p = 0.46).
Univariate correlation coefficients of ANGPTL4 and
PLTP activity with various clinical variables in all sub-
jects combined are shown in Table 2. Plasma ANGPTL4
was correlated positively with PLTP activity (Fig. 1). Both
ANGPTL4 and PLTP activity were correlated positively
with hsCRP (Fig. 2). Furthermore, plasma ANGPTL4
and PLTP activity were both correlated positively with
systolic blood pressure, BMI, glucose, hsCRP and NEFA
levels. Plasma PLTP activity was also correlated posi-
tively with diastolic blood pressure. Plasma ANGPTL4
was correlated inversely with total cholesterol and LDL
cholesterol, whereas PLTP activity was related positively
to triglycerides and apoB, and inversely to HDL choles-
terol (Table 2). Plasma ANGPTL4 was not significantly
correlated with triglycerides.
Using multivariable linear regression analysis, we next
tested the extent to which the relationship of plasma
ANGPTL4 and PLTP activity with hsCRP was
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independent of NEFA, lipids (total cholesterol and tri-
glycerides) and glycemia. ANGPTL4 remained positively
associated with hsCRP when taking account of age, sex,
NEFA, total cholesterol, triglycerides and the presence of
diabetes (Table 3, Model A1) or alternatively of fasting
glucose (Table 3, Model A2). ANGPTL4 was also inde-
pendently associated with hsCRP after further adjust-
ment for the use of metformin, sulfonylurea and
antihypertensives (Model A1: β = 0.320; p = 0.003;
Model A2: β = 0.332, p = 0.001). Likewise, plasma
PLTP activity was positively and independently associ-
ated with hsCRP taking account of either the pres-
ence of diabetes (Table 3, Model B1) or of fasting
glucose (Table 3, Model B2). The relationship of
PLTP activity with hsCRP was still significant after
adjustment for the use of metformin, sulfonylurea and
antihypertensives (Model A1: β = 0.224; p = 0.044;
Model A2: β = 0.266, p = 0.016). In subsidiary analyses
with BMI in addition to age, sex, the presence of diabetes,
NEFA, total cholesterol and triglycerides as dependent
variables, plasma PLTP activity but not ANGPTL4 was in-
dependently associated with BMI (β = 0.239, p = 0.05 and
β = 0.137, p = 0.23, respectively; data not shown).
In view of the observation that plasma ANGPTL4 and
PLTP activity were positively correlated with each other
in univariate analysis, and that both ANGPTL4 and
PLTP activity were independently associated with hsCRP,
we next sought to determine whether the relationship
between plasma ANGPTL4 and PLTP activity was inde-
pendent of plasma glucose, total cholesterol and triglyc-
erides, In age- and sex-adjusted multivariable linear
regression analysis, plasma ANGPTL4 was independ-
ently associated with PLTP activity (Table 4, Model A).
This relationship was essentially unaltered after further
adjustement for the use of metformin, sulfonylurea and
antihypertensives (β = 0.226, p = 0.058). Notably, when
hsCRP was included in the analysis, the relationship be-
tween plasma ANGPTL4 and PLTP activity disappeared
(Table 4, Model B). This finding is consistent with the
possibility that the relationship of plasma ANGPTL4
with PLTP activity is at least in part explained by their
associations with hsCRP.
Discussion
The main novel finding of the present study is that the
plasma ANGPTL4 concentration is positively correlated
with PLTP activity. This relationship remained present
when taking account of age, sex, fasting glucose, NEFA
and lipid levels. Notably, ANGPTL4 was no longer asso-
ciated with PLTP activity after further adjustment for
hsCRP, a marker of low-grade chronic inflammation.
Since our study also shows that ANGPTL4 and PLTP
Table 1 Clinical and laboratory characteristics in 41 subjects with Type 2 diabetes mellitus (T2DM) and in 36 subjects without T2DM
T2DM subjects (n = 41) Non-diabetic subjects (n = 36) P-value
Age (years) 60 (55–67) 51 (45–61) < 0.001
Gender (men/women) (19/22) (9/27) 0.082
Systolic blood pressure (mm Hg) 142 (133–158) 128 (115–141) < 0.001
Diastolic blood pressure (mm Hg) 86 (81–90) 78 (72–90) 0.014
BMI (kg/m2) 27.4 (25.5–33.0) 24.6 (22.5–26.8) 0.001
Waist (cm) 99 (90–107) 84 (76–92) < 0.001
Glucose (mmol/l) 8.4 (7.2–10.2) 5.6 (5.0–6.2) < 0.001
HbA1c (mmol/mol) 49 (43–58) 33 (30–37) < 0.001
hsCRP (mg/l) 1.63 (1.03–2.87) 0.90 (0.42–2.42) 0.031
NEFA (mmol/l) 0.37 (0.29–0.45) 0.29 (0.21–0.35) 0.001
Total cholesterol (mmol/l) 5.53 (4.93–6.07) 5.46 (5.0–6.3) 0.80
Non-HDL cholesterol (mmol/l) 4.14 (3.50–4.86) 3.94 (3.39–4.53) 0.35
LDL cholesterol (mmol/l) 3.50 (2.63–3.93) 3.21 (2.78–3.84) 0.95
HDL cholesterol (mmol/l) 1.21 (1.01–1.60) 1.55 (1.32–1.82) 0.003
Triglycerides (mmol/l) 1.64 (1.21–2.16) 1.16 (0.90–1.76) 0.011
ApoB (g/l) 0.97 (0.81–1.11) 0.86 (0.73–0.96) 0.17
Apo A-1 (g/l) 1.30 (1/18–1.56) 1.46 (1.35–1.60) 0.076
ANGPTL4 (ng/ml) 5.68 (4.30–7.91) 3.42 (2.81–4.80) < 0.001
PLTP (AU) 104.1 (98.5–113.6) 95.2 (83.4–100.0) < 0.001
Data are medians (interquartile range). Differences between subjects with and without T2DM were determined by Mann-Whitney U tests and Chi-square tests
where appropriate. Apo: apolipoprotein; ANGPTL4: Angiopoietin-like 4; BMI: body mass index; HbA1c: glycated hemoglobin; HDL: high density lipoproteins;
hsCRP: high sensitivity C-reactive protein; LDL: low density lipoproteins; NEFA: non-esterified fatty acids; PLTP: phospholipid transfer protein; LDL cholesterol was
calculated in 39 T2DM subjects and in 35 non-diabetic subjects
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activity are each independently associated with hsCRP,
these findings are consistent with the hypothesis that en-
hanced low-grade inflammation may result in increased
circulating levels of both ANGTPL4 and PLTP activity.
This would explain at least in part the positive relation-
ship between ANGTPL4 and PLTP. In addition, given
the different mechanisms whereby ANGPTL4 and PLTP
act on triglyceride metabolism [1–3, 11–15], it is plaus-
ible to postulate that ANGPTL4 and PLTP may act
together to elevate circulating triglycerides under pro-
inflammatory circumstances.
In agreement with several earlier reports [10, 20],
plasma ANGPTL4 was elevated in T2DM subjects.
However, neither the presence of T2DM nor the fasting
glucose concentration predicted plasma ANGPTL4 in
age- and sex-adjusted multivariable linear regression
analysis in which we also accounted for hsCRP, NEFA,
total cholesterol and triglycerides. hsCRP and NEFA
levels were elevated in T2DM, and in view of their inde-
pendent relationships with plasma ANGPTL4, it is likely
that these variables jointly contributed to the higher
ANGPTL4 levels as presently observed in T2DM. On
the other hand in fully adjusted analysis, plasma PLTP
activity remained associated with T2DM or alterna-
tively with fasting glucose, in keeping with other data
[11–13, 23, 27]. In addition, although both plasma
ANGPTL4 and PLTP activity were expectedly correlated
with obesity and NEFA, ANGPTL4 was inversely corre-
lated with total cholesterol and LDL cholesterol, whereas
PLTP activity was significantly correlated with triglycer-
ides [8, 9, 11, 12]. Furthermore, the production of
ANGTPL4 is stimulated by PPARγ activation in vitro [28],
whereas plasma PLTP activity was found to change little
in response to the PPARγ agonist pioglitazone in vivo in
Table 2 Univariate relationships of angiopoietin-like 4 (ANGPLT4)
levels and phospholipid transfer protein (PLTP) activity with clinical
and laboratory variables in 77 subjects (41 subjects with and 36
subjects without Type 2 diabetes mellitus)
ANGPTL4 (μg/l) PLTP (AU)
ANGPTL4 0.309**
Age (years) 0.261* 0.159
Systolic blood pressure (mm Hg) 0.211* 0.286**
Diastolic blood pressure (mm Hg) 0.137 0.268*
BMI (kg/m2) 0.368*** 0.420***
Glucose (mmol/l) 0.341** 0.433***
HbA1c (mmol/mol) 0.447*** 0.390***
hsCRP (mg/l) 0.377*** 0.373***
NEFA (mmol/l) 0.411*** 0.304**
Total cholesterol (mmol/l) −0.230* 0.209
Non-HDL cholesterol (mmol/l) −0.209 0.214
LDL cholesterol (mmol/l) −0.255* 0.178
HDL cholesterol (mmol/l) −0.106 −0.256*
Triglycerides (mmol/l) 0.127 0.431***
ApoB (g/l) −0.032 0.319**
ApoA-I (g/l) −0.054 −0.119
Spearman correlation coefficients. Apo apolipoprotein, ANGPTL4 angiopoietin-like
4, BMI body mass index, HbA1c glycated hemoglobin, HDL high density
lipoproteins, hsCRP high sensitivity C-reactive protein, LDL low density
lipoproteins, NEFA non-esterfied fatty acids, PLTP phospholipid transfer protein.
LDL cholesterol was calculated in 39 T2DM subjects and in 35 non-diabetic
subjects. *p < 0.05; **p < 0.01: ***p < 0.001
Fig. 1 Relationship of plasma angiopoietin-like 4 (ANGPTL4) levels with
phospholipid transfer protein (PLTP) activity 77 subjects (41 subjects
with Type 2 diabetes mellitus (T2DM) and 36 non-diabetic subjects).
Spearman correlation coefficient: 0.309, p = 0.006
Fig. 2 Relationship of plasma angiopoietin-like 4 (ANGPTL4) levels.
a ANGPTL4 and phospholipid transfer protein (PLTP) activity (b)
ANGPTL4 with high sensitivity C-reactive protein (hsCRP) in 77
subjects (41 subjects with Type 2 diabetes mellitus T2DM and 36
non-diabetic subjects. a Spearman correlation coefficient: 0.377,
p = 0.001. b Spearman correlation coefficient: 0.373, p = 0.001
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humans [29]. Thus, the interrelationship between plasma
ANGPTL4 and PLTP activity, even after adjustment for
dysglycemia, NEFA and lipid levels, is remarkable.
ANGPTL4 is upregulated by lipopolysaccharide (LPS)
which likely involves the Toll-like receptor 4 (TRL 4)
[10, 30]. Interestingly, PLTP shares homology with LPS
[12, 31] but while PLTP increases in response to acute
inflammation, it may decrease after LPS administration
[24]. In addition, our unpublished data indicate that the
level of Angptl4 mRNA in rat hepatocytes is markedly
increased by interleukin-1β (IL-1β) and tumor necrosis
factor α (TNFα). On the other hand, the ability of
interleukin-6 (IL-6) to induce TNFα is abolished in
PLTP knockout mice [32], raising the possibility that
TNFα could be involved in interrelation between
ANGPTL4 and PLTP. We used hsCRP as a marker of
enhanced low-grade chronic inflammation, but it seems
unlikely that CRP plays a major direct role in regulating
ANGPTL4 and PLTP. Obviously however, given the
complex and yet to be more precisely delineated pro-
cesses by which inflammatory stimuli affect ANGTPL4
and PLTP regulation, the mechanisms responsible for
the association of a pro-inflammatory state with both
plasma ANGPTL4 and PLTP activity await further study.
Loss of function mutations in ANGPTL4 and genetic
variations in PLTP that attenuate its plasma activity have
been associated with an attenuated risk of coronary ar-
tery disease, emphasizing the relevance of ANGTP4-
and PLTP-mediated processes on the development of
atherosclerosis [33, 34]. Based in the present findings,
we postulate that yet to be more precisely delineated in-
flammatory pathways may give rise to increased plasma
levels of ANGPTL4 and PLTP activity, conceivably con-
tributing to joint effects on triglyceride elevations. Thus,
in the context of low-grade chronic inflammation,
ANGPTL4 and PLTP gene-environment interactions
could aggravate abnormalities in NEFA and triglyceride
metabolism.
Several other methodological issues of the present
study need consideration. The ANGPTL4 ELISA that we
used measures the full length protein and the C-
terminal truncated fragment but does not detect the N-
terminal truncated fragment. The N-terminal but not
the C-terminal fragment carries LPL inhibitory activity.
Concerning PLTP, its activity as reported here reflects
Table 3 Multivariable regression analyses showing independent relationships of angiopoietin-like 4 (ANGPTL4) levels and phospholipid
transfer protein (PLTP) activity with high sensitivity C-reactive protein (hsCRP), glycemia and plasma lipids in 77 subjects (41 subjects with









β p-value β p-value β p-value β p-value
Age 0.173 0.12 0.209 0.065 0.094 0.43 0.119 0.33
Sex (men vs. women) 0.226 0.043 0.263 0.014 −0.135 0.25 −0.057 0.62
T2DM 0.088 0.48 0.376 0.006
Glucose −0.081 0.51 0.276 0.034
hsCRP 0.327 0.002 0.315 0.003 0.229 0.037 0.299 0.034
NEFA 0.360 0.002 0.374 0.001 0.020 0.87 0.105 0.37
Total cholesterol −0.284 0.009 −0.308 0.005 0.014 0.90 0.025 0.83
Triglycerides 0.081 0.47 0.105 0.39 0.10 0.166 0.21
Models A: ANGPTL4 as dependent variable
Models B: PLTP activity as dependent variable
Models 1: including Type 2 diabetes mellitus (T2DM) as independent variable
Models 2: including fasting glucose as independent variable
β: standardized regression coefficient, NEFA non-esterified fatty acids, T2DM Type 2 diabetes mellitus. ANGPTL4, hsCRP and triglycerides are loge transformed
Table 4 Multivariable regression analyses showing relationships
between angiopoietin-like 4 (ANGPTL4) levels and phospholipid
transfer protein (PLTP) activity with high sensitivity C-reactive
protein (hsCRP), glycemia and plasma lipids in 77 subjects (41
subjects with and 36 subjects without Type 2 diabetes mellitus)
Model A Model B
β p-value β p-value
Age 0.139 0.23 0.209 0.065
Sex (men vs. women) 0.239 0.033 0.263 0.014
Glucose −0.069 0.59 −0.081 0.51
NEFA 0.378 0.001 0.374 0.001
Total cholesterol −0.301 0.010 −0.308 0.005
Triglycerides 0.133 0.30 0.105 0.39
PLTP activity 0.244 0.032 0.131 0.25
hsCRP 0.315 0.003
Model A: relationship of plasma ANGPTL4 with PLTP activity with hsCRP not
being included as dependent variable
Model B: relationship of plasma ANGPTL4 with PLTP activity with hsCRP being
included as dependent variable
β: standardized regression coefficient, NEFA: non-esterified fatty acids,
T2DM Type 2 diabetes mellitus. ANGPTL4, hsCRP and triglycerides are
loge transformed
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the level of active PLTP [25, 26]. We preferred to use
this type of activity assay, which is independent of the
endogenous lipoproteins present in the individual pa-
tient samples, because PLTP circulates in an active and
inactive form. Consequently, PLTP activity and mass
levels are not closely related [35–37]. Furthermore, we
excluded diabetic subjects using insulin and lipid lower-
ing drugs in order to obviate confounding due to effects
on glucose and lipid metabolism. As a result, we mainly
included T2DM subjects with rather mild hyperglycemia
and dyslipidemia which would limit the generalizability
of our findings. Also, in view of the cross-sectional de-
sign of the current study, it should be stressed that
cause-effect relationships cannot be established with cer-
tainty. Indeed, PLTP is involved in the innate immune
system, and has been implicated to causally modulate in-
flammatory processes [31, 32]. Finally, we regard the
present findings as preliminary given the limited num-
bers of diabetic and non-diabetic participants.
Conclusion
In conclusion, plasma ANGPTL4 and PLTP activity are
interrelated, which may in part be attributable to a
stimulatory influence of low grade inflammation on
these two protein fators. A pro-inflammatory state could
affect triglyceride metabolism via concerted effects on
ANGPTL4 and PLTP.
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